Cardiac Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Cardiac Amyloidosis Market Outlook

Thelansis’s “Cardiac Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cardiac Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cardiac Amyloidosis Overview

Systemic amyloidosis encompasses a group of diseases characterized by the deposition of misfolded fibrillar proteins in the extracellular matrix. Over 30 different precursor proteins can undergo substantial molecular transformations to form amyloid fibrils in vivo. Two primary types of amyloid commonly infiltrate the cardiac tissue: immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. In systemic amyloidosis, cardiac involvement is the primary cause of morbidity and mortality, irrespective of the specific mechanism underlying amyloid production. Both light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) can affect the heart, leading to symptoms such as heart failure, arrhythmias, and other extracardiac manifestations. AL amyloidosis is relatively rare, while ATTR has varying clinical penetrance and is associated with different variants. The pathophysiology involves the extracellular deposition of misfolded protein amyloid fibrils, compromising ventricular compliance and systolic function. Cardiac biomarkers like NT-proBNP and troponins help assess prognosis in these conditions. Additionally, amyloid infiltration of intramyocardial vessels frequently reduces myocardial perfusion. The conduction system is often disrupted, manifesting in atrial arrhythmias (fibrillation, flutter, or atrial tachycardia) and atrioventricular conduction delays. Ventricular arrhythmias may also occur, although sustained ventricular tachycardia is infrequent. Bortezomib, a proteasome inhibitor used alone or typically in combination with other agents, has become the most commonly employed first-line treatment in AL amyloidosis. It is associated with hematological response rates of up to 90%, with 60% of patients achieving complete response or excellent partial response. No specific regimen has been proven superior in high-risk (stage IIIb) patients. Alternative combination regimens may be more suitable for patients with significant peripheral or autonomic neuropathy, considering the potential neurotoxicity of bortezomib, and for those with underlying lymphoplasmacytic lymphoma. High-dose melphalan followed by autologous stem cell transplantation is associated with the most durable remissions. However, careful patient selection is crucial due to the risk of treatment-related mortality, particularly among older and more debilitated patients, including those with advanced cardiac or autonomic nerve involvement.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: